Our science is inspired by a deep understanding of the biology of disease and powered by our commitment to advancing next-generation medicine. The advanced technology behind our therapies leverages oligonucleotides – small sequences of modified RNA – to precisely target and interact with RNA and DNA. This week, we’re at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society presenting Phase 3 clinical data on our investigational RNA-targeted medicine for hereditary angioedema (#HAE) – a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling in various parts of the body, which can cause severe pain and significantly disrupt daily life.
Don't miss the 2024 Oligo Meeting! Register to attend virtually so you can still enjoy our excellent line-up of speakers and poster presentations. This year's annual meeting is in Montreal, QC, Canada, so the livestream will be available at the local time – Eastern Daylight Time. If you cannot watch in real-time, all presentations will be recorded and posted in the online meeting portal within 36 hours of the live meeting. The recordings are available on-demand in the online meeting portal through December 31, 2024. View the agenda here: https://lnkd.in/gT9WW54Z #ots24 #ots #oligomeeting #oligotherapeutics #oligonucleotide #biotech #biotechnology #science #research #biochemistry #medicine #health #biotechnology #montreal #pharmaceuticals #networking